Danmeda

Danmeda is a precision oncology company dedicated to developing next-generation small molecule therapeutics targeting the DNA damage response (DDR) pathway. The company's lead program, DM-101, is a potent and selective inhibitor of Ubiquitin Specific Peptidase 1 (USP1), designed to treat cancers with homologous recombination deficiency (HRD), such as BRCA-mutated breast and ovarian cancers. By leveraging its expertise in ubiquitin-proteasome system biology, Danmeda aims to provide effective treatment options for patients who have developed resistance to existing PARP inhibitors. The company is currently advancing its lead candidate through IND-enabling studies to transition into clinical-stage development.